Barrett’s Research

See Your Likely GLP-1 Weight Loss, Month by Month

Wondering where this could take you? We'll map a realistic month-by-month projection built on published Phase 3 trial data from STEP, SURMOUNT, and ATTAIN — five medications modeled over a full year, all running privately in your browser.

Updated April 2026

Tell us about your starting point

Diet & exercise level

Your month-by-month outlook

Here's where you might land each month, with a realistic range and your goal in view.

Month 1
218 lbs
Month 2
209 lbs
Month 3
202 lbs
Month 4
196 lbs
Month 5
192 lbs
Month 6
189 lbs
Month 7
187 lbs
Month 8
185 lbs
Month 9
184 lbs
Month 10
183 lbs
Month 11
182 lbs
Month 12
182 lbs
TimelineExpected weightRangeLoss from start% of body weight
3 months202 lbs200203 lbs28 lbs12.4%
6 months189 lbs187191 lbs41 lbs17.7%
9 months184 lbs182186 lbs46 lbs20%
12 months182 lbs179184 lbs48 lbs21%

What this means for you

You’re working toward losing 50 lbs (21.7% of your body weight) — a meaningful goal. A dual GIP/GLP-1 medication, and the strongest average weight loss available right now. In clinical trials it averaged 2022% loss. Over 12 months the expected line lands near 182 lbs, so it may help to give yourself a longer runway or revisit the goal. Either way, that's real progress.

A peek under the hood

Here's how we put your projection together, in five plain steps:

  1. Each medication has a documented average weight-loss range from its largest Phase 3 trial.
  2. We average the low and high ends to draw your “expected” line, then show the full range as a band around it.
  3. A gentle decay curve puts most of the loss in the first 6–12 months before it levels off — just like real life.
  4. Your diet and exercise choice nudges the total by 0.85×, 1.0×, or 1.15×.
  5. “Time to goal” is simply the first month your expected line reaches your target weight.

Everyone's body is different, so please hold these numbers loosely. They're estimates drawn from averages in published clinical trials, and your real results will hinge on your genetics, metabolism, dose titration, consistency, diet, and activity. A recent 23andMe genetics study even found up to a 5x difference in GLP-1 response between genetic profiles. Educational only — not medical advice. Seed data — verify before relying on it.

Questions we hear a lot

We build it from the average weight-loss ranges in each medication's largest Phase 3 trial, then apply a realistic curve so the loss tapers the way it does in real life. It's a population-average picture, so think of it as a thoughtful guide — your own results will depend on your genetics, how your dose is titrated, how consistent you are, and your diet and activity.
Because that's what really happens. In the trials, most of the weight comes off in the first 6–12 months before your body settles at a new set point. We model that with a gentle decay curve so the projection follows the published data rather than a straight line that keeps dropping forever.
Tirzepatide (Mounjaro / Zepbound) leads the pack at around 20–22% average loss, with Wegovy close behind at 15–17%. Ozempic and oral options like Foundayo come in a bit lower — though the right choice for you depends on far more than this one number.
They do, and that's encouraging. We nudge the result by 0.85× for minimal activity, 1.0× for moderate, and 1.15× for a structured, protein-focused routine — a simple way to reflect how much your daily habits can amplify what the medication does.
It's an honest question, and worth knowing upfront: trials consistently show some weight comes back after stopping a GLP-1, because the appetite-calming effect ends. That's why most clinicians treat these as long-term medications. Always talk it through with your doctor before stopping.

Keep exploring

2-minute match quiz

Ready to start losing weight?

Answer six quick questions and we'll point you to the programs that suit your budget, your insurance, and how you want to be cared for.